loading...| Preferred Name |
Sulindac |
|
| Synonyms |
cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid Novo-Sundac (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid Sulindac Sulfoxide Aflodac Algocetil Apo-Sulin Arthrocine Artribid Citireuma Clinoril Clisundac Imbaral MK-231 Reumofil Reumyl SULINDAC Sudac Sulindac Sulinol Sulreuma sulindac |
|
| Definitions |
A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C850 |
|
| Accepted_Therapeutic_Use_For |
Arthritis; inflammatory conditions |
|
| ALT_DEFINITION |
A nonsteroidal anti-inflammatory drug (NSAID) that is being studied as a treatment for cancer. |
|
| CAS_Registry |
38194-50-2 |
|
| CHEBI_ID |
CHEBI:9352 |
|
| Chemical_Formula |
C20H17FO3S |
|
| code |
C850 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04) |
|
| Display_Name |
Sulindac |
|
| FDA_UNII_Code |
184SNS8VUH |
|
| FULL_SYN |
cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid Novo-Sundac (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid Sulindac Sulfoxide Aflodac Algocetil Apo-Sulin Arthrocine Artribid Citireuma Clinoril Clisundac Imbaral MK-231 Reumofil Reumyl SULINDAC Sudac Sulindac Sulinol Sulreuma sulindac |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Sulindac |
|
| Legacy Concept Name |
Sulindac |
|
| Maps_To |
Sulindac |
|
| NCI_Drug_Dictionary_ID |
41538 |
|
| PDQ_Closed_Trial_Search_ID |
41538 |
|
| PDQ_Open_Trial_Search_ID |
41538 |
|
| Preferred_Name |
Sulindac |
|
| prefixIRI |
Thesaurus:C850 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0038792 |
|
| subClassOf |